Acadia Pharmaceuticals IncACAD
Price (close)
$20.68
Market cap
$3.6B
P/E
9.4x
Revenue (TTM)
$1.1B
Net income
$380.5M
Dividend yield
—
1-year total return
-2.5%
Net margin
33.4%
Revenue growth
11.8%
Debt / equity
—
What Acadia Pharmaceuticals Inc does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.1B |
| Net income | -$281.6M | -$167.9M | -$216.0M | -$61.3M | $226.5M | $391.0M |
| Free cash flow | -$143.8M | -$126.8M | -$114.0M | $16.7M | $157.2M | $105.1M |
More on ACAD.
- Acadia Pharmaceuticals Inc summary
- Acadia Pharmaceuticals Inc financial statements
- Acadia Pharmaceuticals Inc key metrics
- Acadia Pharmaceuticals Inc health scores and style box
- Acadia Pharmaceuticals Inc earnings
- Acadia Pharmaceuticals Inc dividends
- Acadia Pharmaceuticals Inc valuation
- Acadia Pharmaceuticals Inc ownership and insiders
- Acadia Pharmaceuticals Inc peers
Figures from Acadia Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.